Mufg Securities Americas Inc. Grows Holdings in Insulet Corporation $PODD

Mufg Securities Americas Inc. increased its holdings in Insulet Corporation (NASDAQ:PODD) by 25.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,560 shares of the medical instruments supplier’s stock after purchasing an additional 318 shares during the quarter. Mufg Securities Americas Inc.’s holdings in Insulet were worth $490,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. American Century Companies Inc. boosted its holdings in Insulet by 34.8% in the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier’s stock worth $302,686,000 after buying an additional 297,734 shares during the last quarter. Nuveen LLC purchased a new position in shares of Insulet during the 1st quarter worth $74,163,000. Kayne Anderson Rudnick Investment Management LLC boosted its holdings in Insulet by 1,316.5% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 193,511 shares of the medical instruments supplier’s stock valued at $50,818,000 after purchasing an additional 179,850 shares during the last quarter. Vanguard Group Inc. grew its position in Insulet by 2.1% in the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier’s stock worth $2,276,553,000 after acquiring an additional 178,976 shares during the period. Finally, AustralianSuper Pty Ltd increased its position in shares of Insulet by 487.5% during the 2nd quarter. AustralianSuper Pty Ltd now owns 205,168 shares of the medical instruments supplier’s stock worth $64,460,000 after purchasing an additional 170,247 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of research firms have commented on PODD. Rothschild & Co Redburn upped their price target on Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research note on Friday, October 3rd. Sanford C. Bernstein restated an “outperform” rating on shares of Insulet in a research note on Friday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. Royal Bank Of Canada lifted their target price on shares of Insulet from $370.00 to $380.00 and gave the company an “outperform” rating in a report on Friday. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and an average target price of $379.65.

Insider Buying and Selling

In related news, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total value of $238,725.63. Following the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.39% of the company’s stock.

Insulet Stock Up 1.9%

Shares of NASDAQ PODD opened at $337.53 on Tuesday. The stock has a market capitalization of $23.74 billion, a price-to-earnings ratio of 102.59, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $354.88. The firm has a 50-day moving average price of $322.16 and a 200 day moving average price of $316.00. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same period in the prior year, the business posted $1.08 earnings per share. The firm’s revenue for the quarter was up 29.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.